Welcome to our dedicated page for Regulus Therapeu news (Ticker: RGLS), a resource for investors and traders seeking the latest updates and insights on Regulus Therapeu stock.
Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical innovator focused on developing microRNA-targeted therapies through advanced oligonucleotide technology. This page serves as the definitive source for official company announcements, research milestones, and regulatory developments.
Investors and researchers will find timely updates on clinical trial progress, including the Phase 1b study of RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD). Our curated news collection provides essential insights into therapeutic advancements, partnership agreements, and strategic initiatives shaping the company's trajectory.
The repository features rigorously verified information across key categories: clinical program updates, financial disclosures, intellectual property developments, and scientific publications. Each entry maintains factual accuracy while highlighting implications for Regulus' position in the precision medicine landscape.
Bookmark this page for direct access to primary source materials from Regulus Therapeutics. Regularly updated content ensures stakeholders maintain current understanding of the company's progress in addressing complex diseases through RNA-targeted therapeutics.
Regulus Therapeutics (Nasdaq: RGLS) announced new data from its Phase 1b clinical trial of RGLS4326 for treating autosomal dominant polycystic kidney disease (ADPKD) during the PKD Connect Conference 2021. The results indicate significant target engagement in kidneys, with increased urinary biomarkers PC1 and PC2, correlating inversely with disease severity. RGLS4326 was well-tolerated, showing no serious adverse events. Preclinical data demonstrated improved gene expression and kidney function in animal models. The trial is ongoing with further cohorts being enrolled.
Regulus Therapeutics (Nasdaq: RGLS) announced its presentation of new preclinical and clinical data on RGLS4326 for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). This will take place at the PKD Connect Conference on June 25, 2021. The Phase 1b trial aims to evaluate safety and efficacy across three patient cohorts, utilizing specific dosing regimens. Jay Hagan, CEO, emphasized the significance of sharing data that supports miR-17 as a therapeutic target. RGLS4326, targeting kidney microRNAs, shows promise in mitigating cyst growth and enhancing kidney function.
Regulus Therapeutics Inc. (Nasdaq: RGLS) provided an update on its Phase 1b clinical trial of RGLS4326 for patients with autosomal dominant polycystic kidney disease (ADPKD). Nine patients in the first cohort received 1 mg/kg doses every other week, leading to a mean increase in polycystin levels of 58% for PKD1 and 38% for PKD2, both statistically significant (p=.0004 and p=.026). The treatment was well-tolerated with no serious adverse events. Regulus plans to present further data at upcoming conferences, with the next cohort results expected in Q3 2021.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced that CEO Jay Hagan will present at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021, at 11:35 A.M. ET. The conference will highlight innovative medicines targeting microRNAs. A live webcast of the presentation will be available on the company's investor relations website, with an archived replay for 30 days post-event. Regulus is dedicated to developing treatments based on its expertise in oligonucleotide drug discovery, bolstered by a strong intellectual property portfolio.
Regulus Therapeutics (Nasdaq: RGLS) announced financial results for Q1 2021, with a cash position of $31.6 million. Their clinical trial for RGLS4326 in treating ADPKD showed promising results, with PC1 and PC2 levels increasing by over 50% and 20%, respectively. RGLS4326 was well tolerated with no serious adverse events. Research and development expenses rose to $3.3 million, while general and administrative costs were $2.5 million. The net loss for the quarter was $6.0 million.
Regulus Therapeutics Inc. (Nasdaq: RGLS) will announce its financial results for Q1 2021 on May 13, 2021, after market close. A conference call will follow at 5:00 PM EDT, where the company will provide updates on its business and financial performance. Regulus specializes in developing innovative medicines targeting microRNAs, leveraging its drug discovery expertise for potential therapeutic applications. Investors are advised to be attentive to upcoming results and corporate updates, especially considering the potential impacts of COVID-19 on operations.
Regulus Therapeutics (Nasdaq: RGLS) announced promising top-line results from the first cohort of its Phase 1b clinical trial for RGLS4326, targeting patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Involving nine patients receiving 1 mg/kg doses, the trial demonstrated the drug's safety, with no serious adverse events and mild, transient effects observed. Notably, a significant increase of over 50% in the biomarker Polycystin 1 was recorded. Data from this cohort will be presented at the upcoming Kidney Week in November 2021.
Regulus Therapeutics Inc (Nasdaq: RGLS) has completed dosing for the first cohort of nine patients in its Phase 1b clinical trial of RGLS4326, focusing on autosomal dominant polycystic kidney disease (ADPKD). This trial aims to assess safety and pharmacokinetics of RGLS4326, with results expected in the coming weeks. The study includes multiple cohorts with varying doses, and RGLS4326 has shown promise in preclinical models by regulating Pkd1 and Pkd2. Notably, the drug is currently under a Partial Clinical Hold by the FDA for extended duration treatment.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced that Jay Hagan, President and CEO, will present at the 20th Annual Needham Healthcare Conference on April 15, 2021, at 1:30 P.M. ET. The event will focus on the innovative medicines targeting microRNAs developed by Regulus.
A live webcast will be accessible on the company's investor relations website, with a replay available for 30 days post-event.
Regulus Therapeutics (RGLS) reported Q4 and 2020 financial results, highlighting revenue of $5 million for the quarter and $10 million for the year, driven by milestones in their collaboration with Sanofi for RG-012. R&D expenses increased to $4 million and $15.3 million for Q4 and the year, respectively, due to ongoing development activities. The net loss narrowed to $1.3 million in Q4 and $15.7 million for the year, compared to higher losses in 2019. Regulus also completed a $19 million private financing and advanced its RGLS4326 program into Phase 1b for ADPKD.
